{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-25-000024","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2025-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.245421+00:00","generated_at":"2026-05-22T22:29:10.044258+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"iBio Q3 FY2025 net loss widens to $4.9M; pipeline progress with IBIO-600, Activin E","bullets":["Net loss from continuing ops $4.9M ($0.49/share) vs $2.6M ($0.71/share) in Q3 FY2024.","R&D expenses doubled to $1.9M on advancing IBIO-600 and Activin E programs.","Cash $5.2M at March 31; after $6.2M warrant inducement in April, cash ~$10.5M as of May 1.","In-licensed first-in-class Activin E antibody from AstralBio; reported NHP data for IBIO-600 showing dose-dependent muscle growth.","Trading began on Nasdaq under IBIO; on track for IBIO-600 regulatory submission in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-25-000024","json":"https://secwatch.observer/filing/0001420720-25-000024.json","markdown":"https://secwatch.observer/filing/0001420720-25-000024.md","text":"https://secwatch.observer/filing/0001420720-25-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000024/0001420720-25-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000024/ibio-20250502x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T22:29:10.044258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}